• Disulfiram: Proteasome Inhibition and Apoptosis in Cancer Re

  2026-07-02

  Disulfiram, an established dopamine β-hydroxylase inhibitor, now drives innovative cancer research by enabling precise induction of apoptotic cell death through proteasomal chymotrypsin-like activity inhibition. Its robust performance in breast and colorectal cancer models, combined with practical versatility, makes it a top-tier reagent for researchers seeking reproducible workflows.

• 17-AAG (Tanespimycin): Applied HSP90 Inhibition in Cancer Mo

  2026-07-02

  17-AAG (Tanespimycin) stands out as a potent HSP90 chaperone inhibitor that destabilizes oncogenic signaling in cancer research models. This article delivers workflow enhancements, advanced applications, and troubleshooting guidance, empowering researchers to capitalize on the mechanistic and translational advantages of 17-AAG from APExBIO.

• AO/PI Double Staining Kit: Practical Guide for Cell Viabilit

  2026-07-01

  The AO/PI Double Staining Kit offers a dual-dye approach for rapid and reliable discrimination of viable, apoptotic, and necrotic cells in a single workflow. It is best suited for researchers requiring actionable cell viability, apoptosis, and necrosis detection in diverse cell biology experiments. This kit is not intended for applications beyond cell viability and death pathway analysis or for clinical diagnostics.

• Axitinib (AG 013736): Reliable VEGFR Inhibition for Lab Assa

  2026-07-01

  This article addresses real-world assay challenges faced by cancer biology researchers using Axitinib (AG 013736), SKU A8370. By examining common pitfalls in experimental design, data interpretation, and vendor selection, it demonstrates how Axitinib from APExBIO offers reproducible, data-driven solutions for angiogenesis inhibition and tumor growth studies.

• Carfilzomib (PR-171): Optimizing Proteasome Inhibition in Mu

  2026-06-30

  Explore how Carfilzomib (PR-171) advances proteasome inhibition strategies in multiple myeloma research. This article delivers new insights into assay design, translational synergy, and preclinical modeling, distinct from standard product summaries.

• Dihydroethidium for High-Fidelity Superoxide Detection in Ce

  2026-06-30

  Dihydroethidium (DHE) empowers researchers to quantify intracellular superoxide with unmatched specificity, supporting advanced oxidative stress and apoptosis studies. By leveraging new insights from cancer nanotherapy and evidence-driven optimization, this guide offers actionable workflows, troubleshooting, and comparative context for robust, reproducible results.

• Immunoproteasome-Driven IL-4Rα Degradation in Type 2 Airway

  2026-06-29

  This study reveals that the immunoproteasome, specifically the LMP7 subunit, facilitates degradation of IL-4Rα and thereby limits type 2 inflammation and airway hyperresponsiveness in asthma models. These findings provide mechanistic insight into how immunoproteasome activity modulates allergic inflammation and suggest new avenues for targeting airway disease.

• Targeting Serine Proteases: AEBSF.HCl in Regulated Cell Deat

  2026-06-29

  This article explores the mechanistic and translational intersections of serine protease activity, lysosomal membrane permeabilization, and necroptosis, with a strategic focus on the application of AEBSF.HCl (4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride) from APExBIO. Drawing on recent advances in necroptosis research, it provides actionable guidance for translational scientists working in cell death, neurodegeneration, and immune-oncology, highlighting both protocol parameters and strategic considerations for leveraging serine protease inhibitors.

• MLN2238 and Proteotoxic Stress: New Frontiers in Proteasome

  2026-06-28

  Discover how MLN2238, a potent proteasome β5 subunit inhibitor, uniquely advances our understanding of proteotoxic stress responses and redox signaling in multiple myeloma and lymphoma research. This article offers technical depth and novel insights not found in prior MLN2238 reviews.

• USP7 Modulates Macrophage Polarization via PKM2 in Acute Pan

  2026-06-27

  This study reveals that ubiquitin-specific protease 7 (USP7) promotes pro-inflammatory macrophage polarization in severe acute pancreatitis by regulating pyruvate kinase M2 (PKM2)-mediated metabolic reprogramming. The findings connect immune cell phenotype, metabolic control, and inflammation, offering new therapeutic directions for SAP and highlighting the role of PKM2 as an intervention point.

• Metal-Ion Chelating L-Phe Nanostructures Enhance ICB in Canc

  2026-06-26

  This study demonstrates that metal-ion-chelating L-phenylalanine nanostructures, when combined with short-term starvation, modulate dendritic cell activation and reverse immune suppression in breast tumors. The findings reveal a novel ion-channel-dependent mechanism that sensitizes tumors to immune checkpoint blockade, providing new strategies for overcoming resistance in solid tumor immunotherapy.

• ONX-0914 (PR-957): Immunoproteasome Inhibition Beyond Autoim

  2026-06-26

  Discover ONX-0914 (PR-957) as a precision tool for dissecting immunoproteasome function—not only in autoimmune disease but also in airway inflammation and cytokine regulation. This article reveals novel insights and advanced research workflows for next-generation immunology.

• Topotecan HCl: Mechanistic Precision for Translational Oncol

  2026-06-25

  This article provides a strategic, evidence-backed exploration of Topotecan HCl as a topoisomerase 1 inhibitor, highlighting its mechanistic underpinnings, translational value in lung and prostate cancer models, and actionable guidance for researchers. Integrating key findings from in vitro drug response methodologies and recent protocol advances, we position APExBIO’s Topotecan HCl as a benchmark for reproducibility and mechanistic fidelity in cancer research.

• Pepstatin A: Applied Aspartic Protease Inhibitor Workflows

  2026-06-25

  Pepstatin A stands out as a precision aspartic protease inhibitor, enabling robust experimental control in viral protein processing and osteoclast differentiation models. This guide dissects real-world workflows, advanced troubleshooting, and the latest translational insights for maximizing Pepstatin A's performance in biomedical research.

• CXCR4-Targeted Theranostics in Lymphoma: Imaging and Therapy

  2026-06-24

  This review synthesizes recent advances in CXCR4-targeted imaging and therapeutic strategies for lymphoma, highlighting how molecular imaging ligands and antagonists enable precision diagnosis and intervention. The study elucidates the biological rationale for CXCR4 as a dual diagnostic and therapeutic target, providing insights into experimental design and translational challenges.

16886 records 1/1126 page Next 12345 下5页 Last page